-
Hiroki Takashima
Division of Developmental Therapeutics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center Innovation Center of NanoMedicine (iCONM)
-
Yoshikatsu Koga
Division of Developmental Therapeutics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center Innovation Center of NanoMedicine (iCONM)
-
Ryo Tsumura
Division of Developmental Therapeutics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center
-
Hirobumi Fuchigami
Division of Developmental Therapeutics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center
-
Yasuhiro Matsumura
Innovation Center of NanoMedicine (iCONM) Department of Immune Medicine, National Cancer Center Research Institute
-
Masahiro Yasunaga
Division of Developmental Therapeutics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center Innovation Center of NanoMedicine (iCONM)
-
Hiroyoshi Y. Tanaka
Department of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
-
Tsuyoshi Kurihara
Department of Pharmaceutical Biomedicine, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
-
Mitsunobu R. Kano
Department of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Department of Pharmaceutical Biomedicine, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
